<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89064">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01929252</url>
  </required_header>
  <id_info>
    <org_study_id>2011/07</org_study_id>
    <nct_id>NCT01929252</nct_id>
  </id_info>
  <brief_title>Postoperative Analgesic Effect Of Dexmedetomidine Administration in Wound Infiltration for Total Abdominal Hysterectomy</brief_title>
  <official_title>Phase 4 Study of Postoperative Analgesic Effect Of Dexmedetomidine Administration in Wound Infiltration For Total Abdominal Hysterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TC Erciyes University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TC Erciyes University</source>
  <oversight_info>
    <authority>Turkey: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to investigate the analgesic efficacy of dexmedetomidine
      administration in wound infiltration for total abdominal hysterectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Abdominal hysterectomy is associated with moderate to severe postoperative pain, effective
      analgesia after hysterectomy essential and several techniques are used such as
      administration of opioids, nonsteroidal anti-inflammatory drugs and wound infiltration of
      local anaesthetics. Different local anaesthetics can be used for the wound infiltration
      techniques.Ifiltration of the surgical wound with bupivacaine following outpatient provides
      pain relief in the postoperative period , allows the early discharge from the outpatient
      surgical units.There has been increased interest in administration of analgesic prior to
      surgical injury. Dexmedetomidine is a highly selective alpha-2 adrenergic agonist with
      sedative , anxiolytic, analgesic, sympatholytic and antihypertensive effects.Dexmedetomidine
      has been used intravenously before initiation of anaesthesia and it has shown to provide
      some analgesic effect after surgery but there were some adverse hemodynamic effects.
      Surgical wound administration of dexmedetomidine may be useful to avoid the adverse
      haemodynamic effects  of intravenous administration while still providing the postoperative
      analgesia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Analgesic Consumption</measure>
    <time_frame>1 day after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pethidine consumption (patient controlled analgesia procedure) was recorded</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>1 day after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visual analog scale on rest and movement was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemodynamic Changes</measure>
    <time_frame>During the surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Arterial blood pressure, heart rate, peripheral oxygen saturation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>%0.25 40 ml levobupivacaine and 2 mcg/kg dexmedetomidine administered via wound infiltration just before the incision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levobupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>%0.25 40 ml levobupivacaine administered via wound infiltration prior to incision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>2mcg.kg-1 dexmedetomidine wound infiltration</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine</intervention_name>
    <description>0.25% levobupivacaine (40ml) wound infiltration</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_label>Levobupivacaine</arm_group_label>
    <other_name>chirocaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-65 yo female

          -  scheduled for elective hysterectomy

          -  no known allergies to drugs

          -  ASA 1=2 patients

        Exclusion Criteria:

          -  history of diabetes

          -  history of chronic pain treatment

          -  pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fatih M. Kurt, Resident</last_name>
    <role>Principal Investigator</role>
    <affiliation>erciyes university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ayse Ulgey, Asst. Prof</last_name>
    <role>Study Director</role>
    <affiliation>erciyes university</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Erciyes university hospital</name>
      <address>
        <city>Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 22, 2013</lastchanged_date>
  <firstreceived_date>August 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>TC Erciyes University</investigator_affiliation>
    <investigator_full_name>Ayse Ulgey</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>dexmedetomidine</keyword>
  <keyword>wound infiltration</keyword>
  <keyword>postoperative analgesia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
